Federal Comment Window on 7-OH Scheduling Closes, With DEA Order Possible as Soon as August 5
The federal comment period on the DEA's proposal to temporarily place concentrated 7-hydroxymitragynine (7-OH) and three synthetic kratom-derived compounds in Schedule I closed July 31, with the HHS request for information on the proposed 7-OH threshold shutting at 11:59 p.m., according to Kratom.news. Concentrated 7-OH remains federally unscheduled until the formal temporary order issues, which by statute cannot happen before August 5. Advocacy groups filed final positions on both sides, with Students for Sensible Drug Policy reporting thousands of opposition comments and the American Kratom Association urging policymakers to target chemically manipulated 7-OH products rather than natural kratom leaf.
The federal comment period on the DEA's proposed temporary scheduling of concentrated 7-hydroxymitragynine (7-OH) closed July 31, removing the last formal channel for outside input before the agency can issue its Schedule I order, according to Kratom.news. The proposal, which the DEA announced July 1, targets concentrated and synthetic 7-OH products above defined thresholds along with three lab-made analogs. Natural kratom leaf, which contains 7-OH only in trace amounts, is outside the proposed order's scope, according to the rule text published in the Federal Register.
What closed, and what did not change
The Department of Health and Human Services opened a 30-day request for information on the proposed threshold for concentrated 7-OH through its Office of the Assistant Secretary for Health, under docket HHS-OASH-2026-0232. That window closed at 11:59 p.m. on July 31, Kratom.news reported. Because standard notice-and-comment procedures do not apply to temporary scheduling, the request for information and the public docket, which had drawn more than 24,000 comments as of late July, served as the main avenues for scientific and public input.
Kratom.news emphasized that nothing changed overnight when the window closed. Concentrated 7-OH remains federally unscheduled until the Attorney General issues the formal temporary scheduling order, which follows analysis of the submitted comments and HHS input, per the outlet's account of the process. By statute, the outlet noted, the order cannot take effect before August 5, 2026.
Final positions, filed on deadline
Students for Sensible Drug Policy said thousands of people mobilized to submit comments opposing the proposed scheduling before the deadline, in an update posted on the group's site. The group argued that overbroad Schedule I placement could drive use underground, hinder research, and harm people who currently use kratom as a self-managed alternative to opioids. SSDP had previously criticized the timing of the comment window, which opened over the July 4 holiday weekend.
Prevention groups pressed in the opposite direction. The Partnership for a Drug-Free New Jersey issued a statement July 30 supporting the DEA's plan to temporarily classify concentrated and synthetic kratom-derived opioids as Schedule I substances, as KNT reported in its coverage of Virginia's new enforcement unit.
The American Kratom Association, which welcomed the July 1 notices as consistent with its distinction between natural leaf and chemically manipulated products, according to Kratom.news, published a statement calling on the American Medical Association and other policymakers to identify what the group called the real public health threat: chemically manipulated 7-OH opioid products, as distinct from traditional kratom leaf. "Chemically manipulated 7-OH opioid products are not natural kratom leaf products," the association said, describing them as high-potency opioid formulations improperly marketed as kratom. The AKA also pointed to National Institutes of Health approval of what it called groundbreaking kratom research, arguing the development supports evidence-based regulation of natural leaf products.
The closing window drew general-audience coverage as well. A Yahoo Finance piece tied to a new Hamilton Morris documentary framed the request for information and the coming scheduling decision around the economic and scientific stakes for manufacturers, retailers, and researchers working with both botanical kratom and synthetic derivatives.
What happens after August 5
Under the notice published July 6, the temporary order would cover plant material with more than 0.050 percent 7-OH by dry weight, finished products containing more than 1 milligram of 7-OH per unit, and three synthetic compounds: mitragynine pseudoindoxyl, MGM-15, and MGM-16. Once the order takes effect, manufacture, distribution, sale, and possession of covered products would be federally prohibited, according to the notice. Kratom.news reported that the temporary control would typically last up to two years, with a possible one-year extension while permanent rulemaking proceeds.
The DEA has not announced a publication date within the eligible window. The agency's notice states only that the order will not issue before August 5.
Sources
-
7-OH Scheduling Timeline After July 31, 2026
Kratom.news
The HHS 30-day Request for Information on the proposed threshold for concentrated 7-OH, docket HHS-OASH-2026-0232, closes on July 31 at 11:59 p.m. Nothing changed overnight at the end of July; concentrated 7-OH remains federally unscheduled until the Attorney General issues the formal temporary scheduling order, which cannot take effect before August 5, 2026.
-
Thousands Mobilize Against DEA's Proposed 7-OH and SR-17018 Bans as July 31 Deadline Nears
Students for Sensible Drug Policy
The advocacy group described thousands mobilizing against the DEA's proposed bans as the July 31 deadline neared, arguing that overbroad Schedule I placement could drive use underground, hinder research, and harm people who currently use kratom as a self-managed alternative to opioids.
-
AKA Statement Calling on the AMA and Policymakers to Distinguish Manipulated 7-OH Products From Natural Kratom Leaf
American Kratom Association
The association called on the American Medical Association and other policymakers to identify the real public health threat as chemically manipulated 7-OH opioid products, not traditional kratom leaf, and pointed to NIH approval of new kratom research.
-
Hamilton Morris Documentary Takes Viewers Inside the 7-OH Scheduling Debate
Yahoo Finance
A media piece tied to a Hamilton Morris documentary discusses the HHS request for information and the upcoming DEA scheduling window, highlighting economic and scientific stakes for manufacturers and retailers of both botanical kratom and synthetic derivatives.